Skip to main content
SpringerLink
Log in

Protein Tyrosine Kinases

From Inhibitors to Useful Drugs

  • Book
  • © 2006

Overview

Editors:
  1. Doriano Fabbro

    1. Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Frank McCormick

    1. UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (11 chapters)

  1. Front Matter

    Pages i-xiii
    Download chapter PDF

  2. Protein Tyrosine Kinases as Targets for Cancer and Other Indications

    • Mark Pearson, Carlos García-Echeverría, Doriano Fabbro
    Pages 1-29

  3. Inhibitors of Signaling Interfaces

    • Carlos García-Echeverría
    Pages 31-52

  4. PI3-Kinase Inhibition

    • Peter M. Finan, Stephen G. Ward
    Pages 53-69

  5. Src as a Target for Pharmaceutical Intervention

    • Mira Šuša, Martin Missbach, Rainer Gamse, Michaela Kneissel, Thomas Buhl, Jürg A. Gasser et al.
    Pages 71-92

  6. Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia

    • Blanca Scheijen, James D. Griffin
    Pages 93-113

  7. JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma

    • Renate Burger, Martin Gramatzki
    Pages 115-144

  8. Glivec® (Gleevec®, Imatinib, STI571)

    • Elisabeth Buchdunger, Renaud Capdeville
    Pages 145-160

  9. Platelet-Derived Growth Factor

    • Tobias Sjöblom, Kristian Pietras, Arne östman, Carl-Henrik Heldin
    Pages 161-186

  10. Structural Biology of Protein Tyrosine Kinases

    • Sandra W. Cowan-Jacob, Paul Ramage, Wilhelm Stark, Gabriele Fendrich, Wolfgang Jahnke
    Pages 187-230

  11. Testing of Signal Transduction Inhibitors in Animal Models of Cancer

    • Terence O’Reilly, Robert Cozens
    Pages 231-264

  12. Phosphoproteomics in Drug Discovery and Development

    • Michael F. Moran, Jarrod A. Marto, Cynthia J. Brame, Olga Ornatsky, Mark M. Ross, Leticia M. Toledo-Sherman et al.
    Pages 265-278

  13. Back Matter

    Pages 279-290
    Download chapter PDF
Back to top

Keywords

About this book

Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.

Editors and Affiliations

  • Novartis Institutes for BioMedical Research Basel, Novartis Pharma AG, Basel, Switzerland

    Doriano Fabbro

  • UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco

    Frank McCormick

Bibliographic Information

  • Book Title: Protein Tyrosine Kinases

  • Book Subtitle: From Inhibitors to Useful Drugs

  • Editors: Doriano Fabbro, Frank McCormick

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1385/1592599621

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Humana Press 2006

  • Hardcover ISBN: 978-1-58829-384-8Published: 01 September 2005

  • Softcover ISBN: 978-1-61737-534-7Published: 01 December 2010

  • eBook ISBN: 978-1-59259-962-2Published: 13 November 2007

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XIII, 290

  • Topics: Biochemistry, general

Publish with us

Policies and ethics

Back to top

Search

Navigation